Novel 17 substituted pregnadiene derivatives as 5α-reductase inhibitors and their binding affinity for the androgen receptor

Chemical and Pharmaceutical Bulletin

Volumn 52, Issue 5, 2004, Pages 535-539

  Cabeza, Marisa ^a   Flores, Eugenio ^b   Heuze, Ivonne ^a   Sánchez, Mauricio ^a   Bratoeff, Eugene ^b   Ramírez, Elena ^b   Francolugo, Victor Alfonso ^c  

^a DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Henri Dunant Hospital   (Mexico)

Author keywords

5 reductase; Androgen receptor; Pregnadiene derivative; Prostate

Indexed keywords

6 METHYLENE 17ALPHA (2 CYCLOHEXYLACETOXY)PREG 4 ENE 3,20 DIONE; 6 METHYLENE 17ALPHA (3 CYCLOHEXYLPROPIONYLOXY)PREG 4 ENE 3,20 DIONE; 6 METHYLENE 17ALPHA (3 CYCLOPENTYLPROPIONYLOXY)PREG 4 ENE 3,20 DIONE; 6 METHYLENE 17ALPHA (4 CYCLOHEXYLBUTYRYLOXY)PREG 4 ENE 3,20 DIONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; PREGNANE DERIVATIVE; PROGESTERONE DERIVATIVE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; ANTIANDROGEN; ENZYME INHIBITOR;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LOCALIZATION; GONADECTOMY; HAMSTER; IC 50; IN VITRO STUDY; MALE; MICROSOME; NONHUMAN; PROSTATE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN BINDING;

ANDROGEN ANTAGONISTS; ANIMALS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; MALE; PREGNADIENES; PROSTATE; PROTEIN BINDING; RECEPTORS, ANDROGEN; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 16544385945     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.52.535     Document Type: Article

References (17)

1. Russell W. D., Wilson J. D., Annu. Rev. Biochem., 63, 25-61 (1994).
2. Li X., Chen C., Singh S. M., Labrie F., Steroids, 60, 430-441 (1995).
3. Labrie F., Sugimoto Y., Luu-The V., Simard J., Lachance Y., Bachvarov D., Leblanc G., Durocher F., Paquet N., Endocrinology, 131, 1571-1573 (1992).
4. McConnel J., Wilson J. D., George F. G., Geller J., Pappas F., Stoner E., J. Clin. Endocrin. Metab., 74, 505-509 (1992).
5. Brooks J. R., Harris G. S., Sandler M., Smither H. J. (eds.), "Design of Enzyme Inhibitor as Drug," Vol. 2, Oxford University Press, Oxford, 1984, pp. 495-542.
6. Berges R. R., Windeler J., Trampisch H. J., Senge T. H., Lancet, 345, 1529-1532 (1995).
7. Awad A. B., Fink C. S., Williams H., Kim U., Eur. J. Cancer Prev., 10, 507-513 (2001).
8. Raynaud J. P., Cousse H., Martin P. M., J. Steroid Biochem. Mol. Biol., 82, 233-239 (2002).
9. Ramírez E., Cabeza M., Heuze I., Gutiérrez E., Bratoeff E., Membrillo M., Lira A., Chem. Pharm. Bull., 50, 15-20 (2002).
10. Cabeza M., Heuze I., Bratoeff E., Murillo E., Ramirez E., Lira A., Chem. Pharm. Bull., 49, 1081-1084 (2001).
11. Cabeza M., Quiroz A., Bratoeff E., Heuze I., Ramirez E., Flores E., Proc. West Pharmacol. Soc., 45, 166-167 (2002).
12. Cabeza M., Bratoeff E., Flores E., Ramírez E., Calleros J., Montes D., Quiroz A., Heuze I., Chem. Pharm. Bull., 50, 1447-1452 (2002).
13. Bratoeff E., Herrera H., Ramírez E., Murillo E., Quiroz A., Cabeza M., Chem. Pharm. Bull., 48, 1249-1255 (2000).
14. Liang T., Cascieri M. A., Cheung A. H., Reynolds G. F., Rasmusson G. H., Endocrinology, 117, 571-579 (1985).
15. Flores E., Bratoeff E., Cabeza M., Ramirez E., Quiroz A., Heuze I., Med. Chem., 3, 225-237 (2003).
16. Bradford M. M., Anal. Biochem., 72, 248-254 (1986).
17. Hirosumi J., Nakayama O., Fagan T., Sawada K., Chida N., Inami M., Takahashi S., Kojo H., Notsu Y., Okuhara M., J. Steroid Biochem. Mol. Biol., 52, 357-363 (1995).